

Index

- α -aminolevulinic acid (ALA), 642.
 See also porphyrias
- abetalipoproteinemia, 608
- abscess, 259
- absence seizures, 95
- Acanthamoeba* species, 279
- acetylcholine receptor antibody, 438
- acetylcholinesterase inhibitors (AChEI), 440
- acute bacterial meningitis (ABM), 238
 antibiotics, empirical therapy for, 240*f*
 clinical presentation, 239
 complications, 241
 CSF abnormalities, 240
 diagnosis, 239
 differential diagnosis, 240
 subarachnoid hemorrhage (SAH), 240
 subdural empyema, 240
 epidemiology, 238
 etiology, 238
 pathology, 239
 pathophysiology, 239
 prevention, 241
 prognostic signs in, 241
 radiological investigations, 239–40
 specific treatment, 240–41
 steroids, role of, 241
- acute demyelinating encephalomyelitis, 34
- acute disseminated encephalomyelitis, 378
 clinical features of, 381
 laboratory findings in, 381
 magnetic resonance imaging features of, 382
 pathological studies of, 384
 treatment of, 382
- acute dystonic reactions (ADR), 191
- acute polio, 212
 clinical features of, 213
 epidemiological features of, 212
 investigations, 213–14
 new polio cases per year, in Norway, 213*f*
 pathophysiological features of, 212
 treatment and management of, 214
- acute retroviral syndrome, 343
- acute severe vertigo, 489–90
- acute tics, 192
- acute viral meningitis
 clinical features of, 308–9
 signs and symptoms of, 309*f*
- acyl-CoA dehydrogenase deficiencies, 632.
 See also fatty acid oxidation disorders
- adrenal leukodystrophy, 607–8
- adriamycin, 530
- adult-onset focal dystonias, 169–70
- Aedes triseriatus*, 325
- age-related macular degeneration (AMD), 501
- akathisia, acute, 191
- ALA dehydratase deficiency porphyria, 640
- albendazole, for treatment of trichinosis
 infection, 300
- alcohol intoxication, acute, 410–11
- alcoholic myopathy, chronic, 413
- alcoholic polyneuropathy, 431
- Alexander's disease, 606
- alkylating agent, 544
- allopurinol, 639
- Alpers' syndrome, 624
- alpha-tocopherol, 405
- alphaviruses
 Eastern equine virus, 326
 laboratory features and management of, 326
 Venezuelan equine virus, 325–6
 Western equine virus, 325
- Alzheimer's disease (AD), 126, 338
 clinical diagnosis of, 127
 clinical features of, 126–7
 epidemiological features of, 126
 investigations, 127
 pathophysiological features of, 126
 treatment options for, 127–8
- American College of Rheumatology (ACR), 45
- amnesia, causes of, 121–2
- amoebic disease, of CNS, 279
 clinical features of, 280
 epidemiological features of, 279
 imaging and pathologic findings in, 280
 investigations, 280
 pathophysiological features of, 279–80
 treatment for, 281*f*
- amygdalohippocampectomy/temporal lobectomy, 113–14
- amyloid precursor protein (APP), 474
- amyotrophic lateral sclerosis (ALS), 199
 clinical features of, 200
 epidemiological features of, 199
 investigations, 200–201
 pathophysiological features of, 199–200
 treatment and management of, 201–2
- anaplastic astrocytomas (AA), 506
- anaplastic oligoastrocytomas, 514, 518
 epidemiology and prognosis, 514
 management of, 516–18
 chemotherapy, 516–18
 surgery and radiation therapy, 516
 pathology and molecular biology, 515
 prognostic factors, 514–15
 treatment, 515
- anaplastic oligodendrogliomas (AOD), 514
- ancestral haplotype (AH), 474
- Andersen's syndrome, 455
- Angiostrongyliasis
 causes of, 301
 clinical features of, 302
 epidemiology of, 301–2
Angiostrongylus cantonensis, 301
- angiotensin-converting enzyme (ACE), 80
- ankylosing spondylitis (AS), 83
 clinical symptoms of, 83
 diagnostic tests, 83
 treatment, 84
- Anopheles* mosquitoes, 327
- anorexia nervosa, 387
- anterior poliomyelitis, acute, 426
- anticardiolipin antibodies (aCL), 59
- antidepressants, 680
- antiepileptic drugs (AEDs), 99, 107, 642
 broad spectrum, 110–11
 choosing the appropriate, 111
 classification of, 111*f*
 narrow spectrum, 107, 110
- antigen presenting cells (APC), 368
- anti-GQ1b ganglioside antibodies, 256
- antimalarial treatment, 288–9
- anti-MuSK antibodies, 439
- antineutrophilic cytoplasmic antigen antibodies, 429
- antinutrophil cytoplasmic antibodies (ANCA), 57
- antiphospholipid antibodies (aPL), 59
- antiphospholipid antibody syndrome (APS), 59
 common manifestation of, 59–60
 diagnosis of, 60
 management of, 60
- antiphospholipid syndrome (APLS), 24
- antipsychotic drugs, 130
- antiretrovirals (ARVs), 354
- antiretroviral toxic neuropathy (ATN), 351
- antithymocyte globulin (ATG), 476
- anti-U3 nucleolar ribonucleoprotein, 71
- apparent diffusion coefficient (ADC), 387
- Aquaporin-4 (AQP-4), 375
- arbovirus prodromes, 310
- Arnold–Chiari malformation, 188
- aromatic *L*-amino acid decarboxylase (AADC), 592
- arousal disorder (AD), 571
 clinical course, 572
 clinical features and differential diagnoses of, 571–2
 epidemiology and risk factors, 571
 investigations, 572
 management, 572
 pathophysiology, 571

- arterial dissection, in children, 33
- arteritic anterior ischemic optic neuropathy (A-AION), 46
- artesanate suppositories, 288
- aseptic meningitis
- acute
- differential diagnosis of, 310
 - clinical features of, 345
 - epidemiological features of, 345
 - methods for investigating, 345
 - non-viral causes of, 311*t*
 - pathophysiological features of, 345
 - treatment and management of, 345
- aspergillosis, 274
- aspirin therapy, 35
- astrocytomas, low grade, 510
- chemotherapy, 512–13
 - clinical features, 510
 - epidemiology, 510
 - investigations, 510
 - PET imaging, 511*f*
 - neuroradiological diagnosis, 511–12
 - pathology and molecular biology, 510
 - prognosis, 511
 - radiation therapy, 512
 - surgery in astrocytoma, 512
 - treatment and management, 511
- ataxia
- acute, 188
 - cerebellar, 187
 - chronic, 188–90
 - diagnosis in patients with, 190
 - etiologies, 189*t*
 - management and prognosis of, 190
 - pathophysiology, 188
 - sensory, 187–8
 - vestibular, 188
- ataxia with vitamin E deficiency (AVED), 406
- atherosclerosis
- of ascending aorta, 6
 - diagnosis of, 7
 - epidemiology, 6
 - of extracranial arteries in neck, 6
 - of intracranial arteries, 6
 - management of, 7
 - pathophysiology and clinical features, 6–7
 - artery-to-artery embolism, 6
 - occlusion, 7
- atherosclerotic disease (LAA), 3
- ATP7B* mutations, 645
- attention deficit hyperactivity disorder (ADHD), 560
- autoimmune disorders, 142
- autonomic dysfunction, 562
- autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE), 101
- etiology, 101
 - prognosis and treatment, 102
- autosomal dominant/recessive progressive external ophthalmoplegia (PEO), 624
- axonal neuropathy, characteristics of, 418
- Baclofen, 371
- bacterial meningitis, 238
- acute. *See* acute bacterial meningitis
- viral meningitis, distinguishing features with, 311*t*
- Balamuthia mandrillaris*, 279
- ballism, 660
- Baló's disease. *See* concentric sclerosis
- Becker muscle dystrophy (BMD), 449, 450
- Becker type muscular dystrophy, 219, 220
- Behçet's disease. *See* Behçet's syndrome
- Behçet's syndrome, 74. *See also* neuro-Behçet's syndrome (NBS)
- arterial-NBS, 75
 - diagnosis of, 74
 - epidemiology of, 74
 - etiopathogenesis, 74
 - extra-axial NBS, 75
 - intra-axial NBS, 75
 - nervous system involvement in, 74–5
 - neurological spectrum of, 75*t*
 - neurological symptom among patients, 75
 - neuromuscular disease in, 76
- benign familial infantile seizures, 101
- benign familial neonatal seizures, 101
- benign hereditary chorea (BHC), 176
- benign nerve sheath tumors, 525
- Betz's cells, 404
- β -2-glycoprotein I antibodies (anti- β -2), 59
- Binswanger's disease
- clinical features of, 12
 - differential diagnosis of, 12
 - epidemiological features of, 12
 - pathophysiological features of, 12
 - treatment and management of, 12–13
- biotinidase deficiency, 615
- bladder dysfunction, 372
- Blastomyces dermatitidis*, 277
- blastomycosis, 277
- blood–brain barrier (BBB), 541, 544
- blood–CSF barrier, 544
- blood glucose levels, 35
- blood–peripheral nerve barrier, 362
- body mass index (BMI), 563
- borderline leprosy, 263
- borderzone infarction (BI), 18
- clinical presentation of, 18
 - investigation, 18–19
 - C-shaped bilateral infarct, 19
 - pathophysiological features of, 18
 - treatment and management of, 19
- Borrelia burgdorferi*, 269, 470
- borreliosis. *See* Lyme disease
- botulism, 445–6
- bovine spongiform encephalopathy (BSE), 336
- Boyle's law, 657
- brachial plexopathies, 432
- brachial plexus, 432, 433*f*
- brain abscess, 242
- clinical features of, 242–3
 - differential diagnosis of, 243
 - etio-pathogenesis, 242
 - mortality due, 244
 - prognosis, 243
 - treatment options in, 243*t*, 244
- brain biopsy, 339
- brain metastases, 539
- incidence of, 539
 - management, 541
 - breast cancer, 541
 - germ-cell tumors, 541–2
 - malignant melanoma, 541
 - non-small-cell lung cancer (NSCLC), 541
 - small-cell lung cancer (SCLC), 541
 - medical management, 539–40
 - presentation and diagnosis, 539
 - prognosis, 539
 - radiation therapy and radiosensitizers, 540
 - specific treatment modalities, 540
 - stereotactic radiotherapy, 540
 - systemic treatment, 541
- brainstem inflammatory lesions, 380
- brain stem tumors, 519
- clinical features, 519
 - conventional-dose chemotherapy, 520
 - emerging therapies, 520–21
 - epidemiology, 519
 - investigations, 519
 - radiation therapy, 520
 - surgery, 520
 - treatment and management of, 519–20
- branch retinal artery occlusion (BRAO), 497
- Brucella*, 255, 547
- brucellosis, 255
- Buerger's disease. *See* thromboangiitis obliterans (TAO)
- burner syndrome, 432
- CADASIL and allied conditions, 37
- callosotomy, 114
- Campylobacter jejuni*, 425
- Canavan's disease, 607
- Candida glabrata*, 274
- Candida parapsilosis*, 274
- Candida tropicalis*, 274
- candidiasis, 274
- carbamazepine, 107
- carcinoid syndrome, 404
- cardiac diseases, 33
- cardiac embolism
- causes of, 14
 - clinical features, 14–15
 - neurological symptoms and signs, 15
 - epidemiology, 14
 - investigations, 15
 - transthoracic echocardiography (TTE), 15–16
 - treatment and management of, 16
 - prevention of recurrence, 16–17
 - thrombolysis/clot retrieval, 16
- carnitine deficiency, 632. *See also* transporter defects
- carnitine O-palmitoyltransferase 2 deficiency, 636
- carnitine palmitoyltransferase deficiency, 632–3. *See also* acyl-CoA dehydrogenase deficiencies
- carnitine palmitoyltransferase II (CPT II) deficiency, 631, 632
- carotidynia, 677
- carpal tunnel syndrome, 437
- Castleman's syndrome, 428
- cataplexy, 558
- cat-scratch disease, 255
- cellular immunity, 45
- central cord syndrome (CCS), 652
- central core disease (CCD), 458
- central nervous system (CNS), 300, 303
- HIV syndromes in, 343

- specific treatment for viral infections of, 319*t*
 subacute and chronic viral infections of, 331
 viruses affecting, list of, 315*t*
- central pontine myelinolysis, 403
- central retinal artery occlusion (CRAO), 497
- central retinal vein occlusion (CRVO), 496
- central serous chorioretinopathy (CSCR), 501
- centronuclear myopathies, 459
- cerebellar ataxic disorders, 188
- cerebellar dysfunction, 531
- cerebellitis, acute. *See* post-viral cerebellitis
- cerebral amyloid angiopathy (CAA), 130
- cerebral hemisphere inflammatory lesions, 380
- cerebral malaria, 285
 antimalarial treatment, 288–9
 caused by *P. vivax*, 286
 clinical features of, 286*t*, 287
 diagnosis of, 287–8
 epidemiological features of, 285
 management of, 288
 non-recommended ancillary treatments
 for, 289*t*
 pathogenesis of coma, 285–6
 pathology, 285
 pathophysiological features of, 285
 poor prognostic factors, 287
 supportive treatment for, 289
- cerebral schistosomiasis, 297
- cerebral toxoplasmosis
 clinical features of, 358
 epidemiological features of, 357
 investigating procedures for, 358
 pathophysiological features of, 357
 treatment and management of, 358
- cerebral venous and sinus thrombosis (CVT), 250
- cerebral venous sinus thrombosis (CVST), 39
 clinical presentation of, 40
 epidemiology of, 39
 investigations, 40
 cerebral angiography, 40
 pathophysiology, 39–40
 treatment and management of, 41
- cerebrosidoses, 602–3
- cerebrospinal fluid (CSF), 300, 305, 308, 351, 368
- cerebrovascular disease, 131
 in children, 33
- cervical disc disease, 580
- cervical plexus, 432
- cervical rib and band syndrome. *See* true
 neurogenic thoracic outlet syndrome
- cervical spondylosis, 582
- cervicocerebral arteries, dissection of, 20
 clinical features, 20
 internal carotid artery, dissection of, 20–21
 investigation, 21
 management of dissection, 21
 pathophysiology, 20
 vertebral artery, dissection of, 21
- cervicogenic headache, 678
- Charcot–Marie–Tooth (CMT) neuropathies, 211
- Charcot–Marie–Tooth disease. *See* hereditary
 motor and sensory neuropathy (HMSN)
- chemotherapeutics, 524
- chemotherapy, 509
- childhood absence epilepsy (CAE), 95
- chloramphenicol, 307
- 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea
 (CCNU), 534
- chloroquine, 289
- chorea
 classification of, 173, 174*t*
 diagnosis and management, 178
 gravidarum, 178
 hereditary causes of, 173
 infectious, 178
 metabolic causes of, 177
- choreoathetosis, acute, 192
- chronic enteroviral encephalomyelitis, 331, 332
- chronic inflammatory demyelinating
 polyneuropathy (CIDP)
 clinical features of, 427
 diagnosis of, 427–8
 epidemiological features of, 427
 pathophysiological features of, 427
 treatment of, 428
- chronic progressive external ophthalmoplegia
 (CPEO), 451
- chronic/tardive syndromes, 192–3
- chronic viral meningitis, 310
- Churg–Strauss disease, 429
- Churg–Strauss syndrome (CSS), 54–5, 57
- circadian rhythm sleep disorders (CRSD), 569
 pathophysiology, international
 classification, 569
 advanced sleep phase type, 569
 delayed sleep phase type, 569
 due to medical condition, 570
 free-running type, 569
 irregular sleep–wake type, 569
 jet lag type, 569
 other circadian rhythm disorders, 570
 shift work type, 569
 treatment, 570
- circulating recombinant forms (CRFs), 342
- cisplatin, 534
- clinically isolated syndrome (CIS), 368
 treatment of, 373
- clinical syndromes, 628*t*
- clonazepam, 183, 574
- Clostridium botulinum*, 445
- Clostridium tetani*, 398
- cluster headache, 671–2
- cocaine, 36
- Coccidioides immitis*, 275
- coccidioidomycosis, 275–6
- Cockayne’s syndrome, 606
- coenzyme Q10 (CoQ10) deficiency, 624
- cognitive impairment, 131, 174
- cognitive impairment and related dementias
 (ACCORD), 117*f*
- CO intoxication, 397
- community-acquired bacterial meningitis
 (CABM), 238
- complicated migraines, 86. *See also* epilepsy
- compound muscle action potentials (CMAPs),
 427, 447
- computerized axial tomography (CT), 105
- concentric sclerosis
 clinical features of, 389–90
 epidemiological features of, 389
 pathology of, 389
 treatment of, 390
- congenital disorders of muscle
 clinical features of, 457
 epidemiological features of, 457
 investigations for diagnosis of, 457–8
 pathophysiological features of, 457
 treatment and management of, 460
- congenital erythropoietic porphyria (CEP), 640
- congenital muscular dystrophies (CMD),
 218, 449
- congenital myopathies, with known gene
 defects, 459*f*
- congenital myopathy with fiber-type
 disproportion (CFTD), 459–60
- congestive myelopathy, 585–6
- convulsive syncope, 86. *See also* epilepsy
- corticobasal ganglionic degeneration
 (CBGD), 153
 clinical features, 154
 epidemiology, 153
 investigations, 154
 management, 154
 neuropathology, 153–4
- corticosteroids, 218, 428
 for treatment of Gnathostomiasis, 301
- craniospinal irradiation (CSI), 530, 544
- creatine kinase (CK), 354, 620
- creatine phosphokinase (CPK), 300
- CREST syndrome, 61
- Creutzfeldt–Jakob disease (CJD), 134, 336
 accidentally transmitted (iatrogenic), 135
 diagnosis, 136
 diagnostic WHO criteria for, 135*t*
 investigations, 135–6
 new variant CJD (vCJD), 135
- critical illness myopathy (CIM)
 characteristics of, 447
 clinical features of, 447
 differential diagnosis of, 448
 epidemiological features of, 447
 investigations for diagnosis of, 447
 pathology of, 448
 pathophysiological features of, 448
 treatment of, 448
- Crohn’s disease, 373, 406
- cryptococcal meningitis, 356
- cryptococcosis, 275
- Cryptococcus neoformans*, 356
- cryptogenic stroke, 14
- Culex tritaeniorhynchus*, 321
- Curschmann–Steinert myotonic
 dystrophy, 452
- cyclophosphamide, 530
- cystic hydatid disease, 296
- cytomegalovirus (CMV)
 clinical features of, 352
 encephalitis, 357
 infection, 340
 treatment and management of, 352
- cytotoxic T cells, 322
- Dantrolene, 371
- Datura* poisoning, 398
- Datura stramonium*, 398
- decompression sickness (DCS), 657
 adjunctive pharmacotherapy, 658
 epidemiology, 657–8

- Dejerine–Klumpke palsy, 432
 Dejerine–Sottas disease, 421
 dementia, 116
 associated with
 ataxia, 141
 HIV infection, 139
 movement disorders, 141–2
 etiologies, 118*f*
 genetic forms of, 118*t*
 potentially reversible/modifiable causes
 of, 119*t*
 treatment for, 117, 119
 dementia with Lewy bodies (DLB), 128, 155–6
 clinical features of, 128–9
 differential diagnosis, 129
 epidemiology, 128
 treatment, 129–30
 demyelinating sensory neuropathy (DADS), 427
 dengue virus, 326
 dentato-rubral-pallido-luysian atrophy (DRPLA),
 141, 176
 dermatomyositis (DM)
 clinical features of, 465
 diagnosis of, 467
 treatment of, 468
 Devic's disease. *See* neuromyelitis optica (NMO)
 dexamethasone, 540
 diabetic lumbosacral radiculoplexopathy, 435
 diabetic neuropathy, 429–30
 diffuse infiltrative lymphocytosis syndrome
 (DILS), 353
 diffusion weighted imaging (DWI), 387
 digital subtraction cerebral angiography (DSA), 34
Diodon hystrix, 398
 Diphtheric polyneuropathy, 426
 disc disease, 579
 cervical, 580
 diagnosis, 581
 lumbar, 580–81
 treatment, 581–2
 disc herniation, 581
 disease modifying therapies (DMT), 369, 372–3
 disseminated intravascular coagulation (DIC), 349
 distal acquired demyelinating sensory (DADS)
 neuropathy, 428
 distal hereditary motor neuropathy
 (distal HMN), 423
 distal myopathies, 236*t*, 452–3
 with anterior tibial compartment phenotype, 235
 clinical features, 235
 epidemiological features of, 235
 investigations, 235, 237
 pathophysiological features of, 235
 treatment and management of, 237
 dopamine neurotransmitter systems, 134
 dopaminergic drugs, 639
 dopa-responsive dystonia (DRD), 169
 doxepin, 680
 doxycycline, 255
 D-penicillamine therapy, 645, 646
 droopy shoulder syndrome, 434
 drug-induced chorea, 177
 drug-induced parkinsonism (DIP), 192
 Duchenne muscular dystrophy (DMD), 219, 449
 vs. BMD, 219–20
 clinical features of, 220
 investigations, 221–2
 pathophysiological features of, 219–20
 scapular winging, atrophy, 221*f*
 treatment and management of, 222
 dural arteriovenous malformations (DAVM), 496
 dural sinus thrombosis, 39. *See also* cerebral
 venous sinus thrombosis (CVST)
 dysarthria, 223
 dysautonomia, 364
 dysferlin, 235
 dyskinesia, 163
 dysphagia, 200, 223
 dystonia, 166
 classification of, 166*t*
 clinical features, 166
 etiology, 167*t*
 genetics, 168
 monogenic forms of, 168
 oppenheim, 168–9
 prevalence of, 170
 routine MRI, 171
 treatment of, 171–2
 dystonia musculorum deformans, 168
 dystrophin gene, 219
 dystrophinopathies, 449
 in females, 450
 DYT1. *See* dystonia musculorum deformans
- Eastern equine virus, 326
 echinococcosis, 295
Echinococcus granulosus, 296
 electroencephalography (EEG), 34, 104
 electromyography (EMG), 354
 electrophysiology, 104
 Emery–Dreifuss muscular dystrophy (EDMD),
 218, 233, 452
 clinical features, 233
 investigations, 233–4
 management, 234
 pathophysiology, 233
 encephalitis, 253
 encephalomyelitis (EAE), 373
 acute, demyelinating, 34
 acute, disseminated. *See* acute disseminated
 encephalomyelitis
 enteroviral, chronic, 331, 332
 encephalopathy with seizures, 267
Entamoeba histolytica, 278, 279
 enterovirus 71. *See* EV71 virus
 enzyme-linked immunosorbent assay (ELISA),
 300, 342, 364
 eosinophilic meningitis, 300
 eosinophilic myeloradiculitis, 300
 ependymomas, 522
 epidermal growth factor receptors (EGFR), 530
 epidural abscess, 248
 clinical features, 248
 common causative organisms in, 249*t*
 epidemiology/pathophysiology, 248
 investigations, 248–9
 treatment and management of, 249
 epidural metastases, 546
 epilepsy, 85, 642
 age and seizure types, 85
 differential diagnosis, 86
 in elderly, 87
 etiology of epileptic seizure disorders, 86
 evaluation of patients with, 86
 mortality, 85–6
 relative risk (RR) of, 86
 surgery
 curative procedures, 113–14
 indications for, 112
 palliative procedures, 114–15
 semi-invasive and invasive video-EEG,
 112–13
 treatment of, 87
 in women, 87–8
 epilepsy with grand mal seizures on awakening
 (EGMA), 95
 epilepsy with myoclonic absences (EMA), 94
 Epstein–Barr virus (EBV), 330, 360, 425, 426
 Erb–Duchenne palsy, 432
 erythrocyte sedimentation rate (ESR), 47, 300
 erythropoietic porphyrias (EP), 641
 erythropoietic protoporphyria (EPP), 640
 esinophilic meningitis, 299*t*
 ethosuximide, 107
 ethylenediaminetetraacetic acid (EDTA), 307, 392
 EV71 virus, 327
 excessive daytime sleepiness (EDS), 557, 558,
 561–2
 extracranial granulomatous arteritis. *See* giant cell
 arteritis (GCA)
- Fabry's disease, 423, 603
 facial pain, 675
 facioscapulohumeral muscular dystrophy
 (FSHD), 223, 451
 clinical features, 223
 epidemiology, 223
 investigations, 223–4
 pathophysiology, 223
 familial amyloid polyneuropathy (FAP), 423
 familial lateral temporal lobe epilepsy
 (FLTLE), 102
 familial mesial temporal lobe epilepsy
 (FMTLE), 102
 familial partial epilepsy with variable foci, 102
 familial periodic paralyses (FPP)
 clinical features of, 454–5
 diagnosis of, 455
 treatment and management of, 456
 fat-soluble vitamins, 401
 fatty acid oxidation disorders, 631
 clinical features and pathophysiology, 632–3
 epidemiology and genetics, 631
 investigations, 633
 prenatal diagnosis of, 633
 felbamate, 110
 fetal alcohol syndrome, 414–15
 fibromuscular dysplasia, 34
 fibromyalgia (FM), 679
 clinical features and diagnosis, 679–80
 epidemiological features of, 679
 management of, 680
 pathogenesis, 679
 fibrous dysplasia, 583
 fleaborne spotted fever, 303
 floppy infant syndrome, 596
 algorithm for diagnosis of, 598*f*
 clinical evaluation of, 596

- diagnostic approach, 598
laboratory investigations, 596–8
possible causes of, 597*t*
- flower-cells, 364
- fluid-attenuated inversion recovery (FLAIR), 320, 338, 376*f*
- focal median neuropathy, 436
- food poisoning, 395
- forced vital capacity (FVC), 202
- Friedreich's ataxia, 423
- frontal lobe epilepsy (FLE), 103
- frontotemporal dementia (FTD), 132, 156
clinical features and diagnosis of, 132–3
differential diagnosis of, 134
epidemiological features of, 132
frontal (behavioral-dysexecutive) variant (fvFTD), 133
investigations, 133
pathological features of, 133–4
progressive non-fluent aphasia (PNFA), 133
semantic dementia (SD), 133
therapy, 134
- Fugu poecilonotus*, 398
- functional MRI, 105–6
- fundus fluorescein angiography (FFA), 495
- fungal infections, of CNS, 274
- GABA neurotransmitter disorders, 592–3
gabapentin, 107, 110
GABA transaminase (GT) deficiency, 593
gait disturbance, 152
assessment of, 195
classification of, 194–5
mental aspects of, 195
treatment, 195
- γ-aminobutyric acid (GABA).
See gamma-aminobutyric acid (GABA)
- gamma-aminobutyric acid (GABA), 402, 642
- Ganciclovir, 352, 357
- gangliosidosis, 601–2
- Gayet-Wernicke encephalopathy, 402
- giant cell arteritis (GCA), 45
clinical manifestations, 45
large-vessel arteritis, 46
neurological manifestations, 46
neuro-ophthalmic manifestations, 46
polymyalgia rheumatica, 46–7
systemic inflammatory syndrome with, 47
systemic manifestations, 45–6
- diagnostic approaches, 47
diagnosis of, 47
imaging, 47
laboratory findings, 47
pathogenesis, 45
cellular immunity (vascular lesion), 45
humoral immunity, 45
prognosis, 48
treatment of, 47
- Glasgow Coma Scale, 318
- glatiramer acetate (GA), 373
- glaucoma, 499
acute, 498–9
- glial fibrillary acidic protein (GFAP), 606–7
- glioblastoma multiforme (GBM), 506
- globoid cell leukodystrophy, 607
- glossopharyngeal-vaguglossopharyngeal neuralgia, 676–7
clinical features, 676
epidemiology, 676
neuroimaging method, 676
pathophysiology, 676
treatment and management, 677
- glucocorticoids, 476
- glucose-6-phosphate dehydrogenase (G6PD) deficiency, 307
- glutaryl CoA dehydrogenase, 614
- GLUT-1 deficiency, 636–7
- glycogenoses, 605
- Gnathostoma spinigerum*, 300
- Gnathostomiasis
causes of, 300
clinical features of, 300–301
epidemiology of, 300
treatment of, 301
- granulocyte-macrophage colony stimulating factor (GM-CSF), 361
- granulomatous amoebic encephalitis (GAE), 279
- Guillain-Barré syndrome (GBS), 321, 352, 409
clinical features of, 425–6
epidemiological features of, 425
investigating procedures for, 426
pathophysiological features of, 425
treatment of, 426–7
- Haemaphysalis* ticks, 323
- half asleep hallucinations, 558
- Hallervorden-Spatz syndrome, 141
- hallucinations, 558
- hand-foot-mouth disease, 327
- Hansen's disease. See leprosy
- Hartnup's disease, 404
- Hauptmann-Thannhauser muscle dystrophy (HTMD), 452
- headache, 506
- headache (HA) syndromes, 577, 673–4
- hearing loss, common presentations of, 493
- hematological diseases, 23
heparin cofactor II and fibrinolysis factors, defect in, 24
homocysteinemia, 24
hyperviscosity, 23
prothrombotic coagulation abnormalities, 23–4
thrombotic thrombocytopenic purpura (TTP), 24
- hematocytosis, 43
- heme synthesis, 641*f*
- hemispherectomy, 114
- hemorrhagic strokes, 25
- hepatic porphyrias, 640–642. See also porphyrias
- hepatocerebral crises, 631
- hereditary folate malabsorption, 637
- hereditary inclusion body myopathies (hIBM), 474
- hereditary liability to pressure palsies (HNPP), 419
- hereditary motor and sensory neuropathy (HMSN), 419
- hereditary neuralgic amyotrophy (HNA), 433
- hereditary neuropathies, classification of, 419
- hereditary neuropathy with pressure palsies (HNPP), 421
- hereditary sensory and autonomic neuropathy (HSAN), 419, 422
- hereditary spastic paraplegia (HSP), 204, 205
clinical features of, 205
epidemiological features of, 205
investigations, 207
pathophysiological features of, 205
treatment and management of, 207
- herpes simplex encephalitis
clinical and laboratory features of, 320
epidemiological features of, 319
management and prognostic factors of, 320
pathogenesis of, 319–20
pathological features of, 320
- herpes simplex viral infection, 310
- herpes zoster, clinical features of, 352
- Hib meningitis in children, 241
- high grade astrocytomas (HGA), 506
clinical features, 506–7
epidemiology, 506
investigations, 507
pathology and molecular biology, 507
prognostic factors, 507–8
radiological assessment, 507
treatment challenge for, 508–9
- highly active antiretroviral therapy (HAART), 284, 332, 341, 351
- Histoplasma capsulatum*, 277
- histoplasmosis, 277
- HIV-associated neuromuscular weakness (HANWS), 354
- HIV-associated predominantly sensory polyneuropathies
clinical features of, 351
epidemiological features of, 351
treatment and management of, 351–2
- HIV myopathy
clinical features of, 354
epidemiological features of, 354
investigating procedures for, 354–5
pathophysiological features of, 354
treatment and management of, 355
- Hodgkin's lymphoma, 548
- homocysteinemia, 24
- homocystinemia, 614
- homocystinuria, 614
- Hormone-induced hypercoagulability, 56
- human African trypanosomiasis, 291–2
- human epidermal growth factor receptor 2 (HER2), 544–5
- human immunodeficiency virus (HIV) disease, 139
classification of, 343
cognitive impairment in, 346
epidemiological features of, 340
method for investigating, 341
myelopathies in, 349
pathophysiological and clinical features of, 340
and related disorders in children, 347–9
and related neurological complications, 340
treatment and management of, 341
- human T-cell leukemia (HTLV), 403
- human T-lymphotrophic virus type 1 (HTLV-1)
clinical features of, 363
epidemiological features of, 362
pathophysiological features of, 362–3
- humoral immunity, 45
- Hunter's syndrome, 604

- Huntington's disease (HD), 140–41, 173
 clinical features of, 174
 differential diagnosis of, 174–5
 genetics, 174
 neuropathological features of, 175–6
 treatments in, 176
- Hurler's syndrome, 604
- hydroxethylstarch (HES), 31
- 4-hydroxybutyric aciduria, 592
- 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA), 7
- hydroxyurea, 530
- hyperammonemia, 611
- hyperhomocysteinemia, 24
- hyperkalemic periodic paralysis, 454–5
- hypersensitivity angitis, 55
- hypertension, 9
- hypertensive encephalopathy, 37
- hypo- and hyperthyroidism, 139
- hypodense lesions, 300
- hypokalemic periodic paralysis, 454
- hypoxanthine guanine phosphoribosyltransferase deficiency, 638
- hypoxic ischemic encephalopathy, 594
- idiopathic brachial plexus neuropathy.
See neuralgic amyotrophy
- idiopathic childhood occipital epilepsy, 101
- idiopathic CNS vasculitis (ICNSV), 49
 treatment, 50
- idiopathic hypersomnia (IH), 561
 clinical assessment, 561
 differential diagnoses for, 561*t*
 epidemiology, 561
 pathophysiology, 561
- idiopathic hypersomnolence (IH), 578
- idiopathic intracranial hypertension (IIH), 672–3
- idiopathic LRE, 99
- idiopathic orbital inflammatory syndrome (IOIS), 498
- immune-mediated chorea, 177
- immunopathogenesis, 466–7
- inactivated polio vaccine, 212
- inappropriate emotional expression disorder (IEED), 200
- inclusion-body myositis (IBM), 363, 465
- incontinentia pigmenti (IP), 484
- indeterminate leprosy, 263–4
- infection, in prenatal, perinatal, or postnatal period, 595
- infectious disorders, 33
- infectious neuropathies, 430–31
- inflammatory demyelinating diseases (IDD), 375
- inflammatory demyelinating
 polyneuropathies (IDPs)
 clinical features of, 352
 investigating procedures for, 352
 pathophysiological features of, 352
 treatment and management for, 352
- inflammatory demyelinating syndromes (IIDS)
 clinical features of, 378
 diagnosis of, 378–9
 epidemiological features of, 378
 pathophysiological features of, 379
 treatment of, 379
- inflammatory spondyloarthropathies, 83
- insomnia, 554
 clinical features of, 554–5
 cognitive control, 556
 diagnosis and differentiation of, 555*t*
 epidemiology, 554
 investigations, 555
 management strategies, 555
 paradoxical intention, 556
 pathophysiology, 554
 sleep restriction therapy, 556
 stimulus control, 555
 treatment and management, 555
- International Headache Society (IHS), 36
- International League against Epilepsy (ILAE), 85
- intracerebral hemorrhage (ICH), 25
 caused by arteriovenous malformation (AVM)
 clinical features, 29
 epidemiology, 28–9
 investigations, 29
 pathophysiology, 29
 prognosis, 29
 risk factors, 29
 treatment, 29
- clinical features, 26
 epidemiology, 25
 EUSI and AHA/ASA guidelines for
 management, 27–8
 investigation, 26–7
 pathophysiology, 25–6
 brain edema, 26
 hematoma enlargement, 26
 prognosis of, 27
 risk factors, 25
 treatment, 27–8
 antiplatelet agents and, 28
 surgical treatment, 28
- intracranial ependymomas, 522–3
- intracranial epidural abscesses. *See* epidural abscess
- intracranial granulomatous arteritis, 49
- intracranial pressure (ICP), 506
- intracranial recordings, 105
- intrathecal chemotherapy, 361
- intravenous drug users (IDU), 362
- intravenous immunoglobulins (IVIGs), 354, 472
- intravenous immunoglobulin therapy (IVIg), 476
- intraventricular hemorrhage, 594
- invasive fungal rhinosinusitis, 276
- ischemic heart disease (IHD), 9
- ischemic myelopathy, acute 584–5
- ischemic stroke, in children, 33
- Ixodes* ticks, 323
- Japanese encephalitis
 clinical features of, 322
 epidemiology of, 321
 laboratory features of, 322
 pathogenesis and pathological features of, 321–2
 prevention and management of, 322
- JC virus (JVC), 358
- juvenile absence epilepsy (JAE), 95
- juvenile myoclonic epilepsy (JME), 96
- juvenile segmental spinal muscular atrophy, 211
- Kaposi's sarcoma (KS), 340
- Karnofsky Performance Score (KPS) scale, 508
- Kawasaki's disease, 55
- Kearns–Sayre syndrome (KSS), 231, 619
- Klüver–Bucy syndrome, 320
- Korsakoff's amnesia. *See* Wernicke–Korsakoff syndrome (WKS)
- Korsakoff's amnesic syndrome, 431
- Korsakoff's syndrome, 121, 402
- Krabbe's disease, 607
- Kunjin encephalitis viruses, 327
- Kuru, 336
 symptoms of, 337
- LaCrosse encephalitis, 325
- lactic acidosis, 621
- lacunar infarcts
 clinical features of, 9–10
 epidemiological features of, 9
 incidence of, 9
 investigations, 10
 pathophysiology, 9
 treatment and management of, 10
 acute stroke therapy, 10
 secondary prevention, 10–11
- Lafora's disease, 96–7
- Laing and Udd distal myopathies, 235
- Lambert–Eaton myasthenic syndrome (LEMS)
 clinical features of, 443
 epidemiological features of, 442
 investigations for diagnosis of, 443
 pathophysiology features of, 442
 treatment and management of, 443
- lamotrigine, 110
- Langerhans' cells, 344
- latex agglutination test (LACT), 275
- Leber's hereditary optic neuropathy (LHON), 498, 622
- Legionella pneumophila*, 470
- Legionnaires' disease, 256
- Leigh syndrome (LS), 622
- Lennox–Gastaut syndrome (LGS), 93–4
- lepomatous leprosy (LL), 263
- lepromin test, 265
- leprosy, 262
 antileprotic treatment, 265
 bacteriology and epidemiology, 262
 cardinal signs of, 264
 clinical and histopathological classification of, 263*t*
 clinical features, 262
 definitive diagnosis of, 264
 differential diagnoses of, 265
 lepromin test, 265
 pathogenesis and immunity, 262
 reactions, 264
 treatment, of reactions, 265
- leptomeningeal disease, 361
- leptomeningeal metastasis (LM), 543
 chemotherapy, 544–5
 diagnosis of, 543–4
 MRI, 543
 pathogenesis, 543
 radiation therapy (RT), 544
 treatment, 544
- Lesch–Nyhan disease (LND), 638
 clinical features of, 638–9
 epidemiological features of, 638
 investigations, 639

- pathophysiological features of, 638
treatment and management of, 639
- lesionectomy, 114
- leukodystrophies, 606
- levetiracetam, 110
- Lewis–Sumner syndrome (LSS), 427
- limb-girdle muscular dystrophy (LGMD), 215, 450
classification of, 216*t*
clinical features of, 216–17
differential diagnosis of, 217–18, 221*t*
epidemiological features of, 215
investigations, 217
pathophysiological features of, 215–16
patient with LGMD2I, 217*f*
treatment and management of, 218
- limb-girdle muscular dystrophy phenotype (LGMD2B), 235
- limbic encephalitis (LE), 552
- lipidoses, 600
- Listeria monocytogenes*, 238, 254
- liver function tests (LFTs), 373
- localization-related epilepsies (LRE), 99
- lomustine, 515
- longitudinally extensive spinal cord lesions (LESCLs), 369
- louse-transmitted diseases, 303
- low pressure headache, 673
- Lucio's leprosy, 264
- lumbar disc disease, 580–81
- lumbar spinal stenosis, 582–3
- lumbosacral plexopathy, 435
- lupus anticoagulant (LA) antibodies, 59
- lyme disease, 269
chronic, 272
clinical expression, 269–70
demographics, 269
diagnosis, 270–71
epidemiology, 269
extraneural manifestations, 270
neurologic involvement, 270
pathogenesis, 272
pathophysiology, 272
preventive strategies, 272
therapy, 271–2
tick vector, 269
- lyme neuroborreliosis, 548
- lysine and tryptophan metabolism, disorders of, 614–15
- magnetic resonance imaging (MRI), 105
- magnetic resonance spectroscopy, 106
- magnetoencephalography (MEG), 105
- major histocompatibility complex (MHC), 354
- malaria, 278
- malignant peripheral nerve sheath tumors (MPNSTs), 525–6
- manganese crusher's disease, 392
- maple syrup urine disease, 609
clinical presentation, 609
diagnosis, 609–10
epidemiology, 609
treatment, 610
- Marchiafava–Bignami disease, 412
- Maroteaux–Lamy syndrome, 605
- maternally-inherited Leigh syndrome (MILS), 622
- MCAD gene, 631
- McArdle's disease, 606
- measles inclusion body encephalitis, 331
- Mediterranean spotted fever (MSF), 306
- medium chain acyl-CoA dehydrogenase (MCAD), 631
- medulloblastomas (MB), 530
clinical risk factors, 532–3
diagnosis and surgery, 531
histologic differentiation, 533
- M (metastatic) stage, 532*t*
- molecular studies, 533
- non-contrast CT scan, 532*f*
- risk stratification for children, 532*t*
- staging evaluation, 531–2
treatment, 533–4
- MELAS A3243G mutation, 625
- melatonin, 574
- memory disorders, 120
- Mendelian genetics, 480–82
- meningiomas, 528
clinical presentation, 529
epidemiology, 528
investigations, 529
pathophysiology, 528
treatment, 529–30
- meningitis, 267, 306
- Menkes' disease, 635
- metabolic disturbances, 37
- metabolic neuropathies, 429
- metabolism, inborn errors of, 595
- metachromic leukodystrophy, 607
- metamphetamine, 36
- metastatic epidural spinal cord compression (MESCC), 546
clinical presentation, 546
diagnosis, 546–7
differential diagnosis, 547–8
epidemiology, 546
pathophysiology, 546
prognosis, 548
treatment of, 548
- methanol toxicity, 499
- methylcobalamin, 402
- methylenetetrahydrofolate reductase gene, 12
- methylguanine-DNA-methyltransferase (MGMT), 514
- methylprednisolone (MP), 372
- migraine headache, 669–71
- migraine-like headaches, 621
- mild cognitive impairment (MCI), 123
clinical features, 123–4
CSF biomarkers, 124
epidemiology, 123
investigations, 124
neuroimaging, 124
pathophysiology, 124
treatment of, 124–5
- Miller–Fisher syndrome, 425
- mini mental state examination (MMSE), 10
- mitochondrial diseases, 617
- mitochondrial disorders, 482
- mitochondrial encephalomyopathies, 617.
See also mtDNA mutations and associated disorders
- mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS), 36, 620
characterization, 620
treatment of, 621
- mitochondrial genetics, 617
genomic organization, 617
heteroplasmy and threshold effect, 619
mitochondrial DNA inheritance and transmission, 618–19
mitochondrial respiratory chain, 618*f*
mtDNA replication and, 617
segregation, 619
- mitochondrial neurogastrointestinal encephalomyopathy (MNGIE), 624
- mitochondrial tRNA^{Lys} gene, 621
- mixed connective tissue disease (MCTD), 72
clinical features, 72–3
epidemiology, 72
investigations and diagnosis, 73
pathophysiology, 72
treatment, 73
- Mollaret's meningitis, 310
- monoamine neurotransmitter disorders, 590
aromatic *L*-amino acid decarboxylase (AADC) deficiency, 592
GTP cyclohydrolase I deficiency, 590
tyrosine hydroxylase (TH) deficiency, 591–2
- monoclonal gammopathy of unknown significance (MGUS), 428
- monogenic focal epilepsies, 101
- monomelic juvenile SMA, 211
- mononeuropathies, 435–7
- mononeuropathy multiplex, 353
- Morquio's syndrome, 605
- movement disorder, 144
classification of, 144*t*
key features of different types of, 144*t*
- movement disorders, 86–7. *See also* epilepsy
- moyamoya, 33
- mtDNA, disorders of, 619
classification of disorders, 620*t*
- mtDNA LHON mutations, 625
- mtDNA mutations and associated disorders, 621
clinical features of mitochondrial diseases, 626*t*
computed tomography (CT) scans, 627
electroencephalography (EEG), 627
epidemiology, 625
exercise testing with near-infrared spectroscopy, 627
gene therapy for mtDNA disorders, 629
investigations, 625–6
laboratory evaluation, 626–7
molecular genetic testing, 628
muscle biopsy, 627
neurological manifestations, 625
pharmacological therapy, 629
symptomatic therapy, 628–9
therapy for mitochondrial diseases, 628
- mtDNA syndromes, 625
- mucopolidoses, 603
- mucopolysaccharidosis, 604
- mucormycosis, 276
- multicore (multi-minicore) disease, 458
- multifocal acquired demyelinating sensory and motor neuropathy (MADSAM), 427
- multifocal acquired motor axonopathy (MAMA), 428

- multifocal motor neuropathy (MMN), 428
- multilobar resections, 114
- multiple sclerosis (MS), 204
 - clinical presentation of, 368–70
 - common neurological signs in, 369*t*
 - diagnosis of, 370
 - epidemiological features of, 366–7
 - pathogenesis and etiology of, 368
 - pathology of, 367–8
 - symptoms in, 369*t*
 - treatment of, 371
- multiple sleep latency test (MSLT), 559, 562
- multiple subpial transactions (MSPT), 114
- multiple system atrophy (MSA), 154
 - clinical domains, features, and criteria for diagnosis of, 155*t*
 - clinical features, 154–5
 - epidemiology, 154
 - investigations, 155
 - management, 155
 - neuropathology, 154
- murine typhus, 303
- Murray Valley encephalitis, 327
- muscle cramps
 - clinical approach to, 461–2
 - diagnostic approach to, 462–3
 - disorders of, 462*t*
 - miscellaneous conditions with, 463*f*
 - phenomenological features of, 461
 - therapeutic approach to, 463
- mushroom poisoning, 395
- myasthenia gravis (MG)
 - clinical features of, 439
 - drugs that can worsen, 440–41
 - epidemiological features of, 438
 - pathophysiology features of, 438–9
 - treatment and management of, 440–41
- Mycobacterium avium* (MA), 261
- Mycobacterium tuberculosis*, 547
- Mycoplasma pneumoniae*, 253, 256, 425
- myelopathies, 584–6
- myoclonic-astatic epilepsy, 96
- myoclonic disorders. *See* myoclonus
- myoclonic epilepsy with ragged red fibers (MERRF), 97–8
- myoclonic seizures, 96
- myoclonus, 179
 - classification, 179
 - clinical etiology classification, 181
 - clinical neurophysiology, 179
 - common dosage of agents for, 182*f*
 - evaluation, 182
 - examination findings, 179
 - features of, 181
 - drug-induced myoclonus, 182
 - essential myoclonus, 181
 - metabolic conditions, 181–2
 - neurodegenerative disorders, 181
 - post-hypoxic myoclonus, 181
 - treatment of, 182–3
- myoclonus epilepsy and ragged-red fibers (MERRF), 621
- myoglobinuria
 - acquired causes of, 479
 - causes of, 477
 - hereditary causes of, 477–8
- myokymia, 461
- myositis, acute, 71
- myotonia, 461
- myotonic dystrophies, 227, 227*f*, 452
 - clinical features, 227–9
 - epidemiology, 227
 - pathophysiology, 227
- myotonic dystrophy type 1 (DM1), 227
- myotonic dystrophy type 2 (DM2), 229
- N*-acetyl aspartate (NAA), 367
- Naegleria fowleri*, 279
- narcolepsy, 557, 578
 - clinical features, 558
 - diagnosis, 558–9
 - epidemiology, 557
 - pathophysiology, 557–8
 - pharmacological management of, 559*t*
- nDNA, disorders of, 622
 - classification of, 623*t*
- neck pain and headache, 677
- Neisseria meningitidis*, 238
- nemaline myopathy (NM), 458
- nerve biopsy, 392, 418
- nerve conduction velocity (NCV), 399
- nerve sheath tumors, 525
 - diagnosis of, 526
 - treatment of, 526–7
- neuralgias and neuropathic syndromes, 664–5
- neuralgic amyotrophy, 432, 435
- neuroacanthocytosis, 176
- neuro-Behçet's syndrome (NBS), 75
 - cerebral venous sinus thrombosis (CVST) in, 78
 - diagnostic studies in, 76–7
 - differential diagnosis of intra-axial, 77
 - intra-axial NBS, acute episodes, 78
 - intra-axial NBS, long-term treatments, 78
 - neurological involvement in, 77
 - subclinical, 76
 - treatment, 78
- neurocutaneous disorders, 483
- neurocysticercosis (NCC), 294
 - clinical features, 294
 - epidemiology, 294
 - hydrocephalus due to, 295
 - neuroimaging studies, 294, 295*f*
 - pathophysiology, 294
 - treatment, 295
- neurodegenerative disorders, 624
- neurofibromatosis, 483, 526
- neuroimaging, 105
- neurological diseases, with trinucleotide repeats and anticipation, 482*t*
- neurological disorders, alcohol-related
 - acute alcohol intoxication, 410–11
 - alcoholic cerebellar degeneration, 411–12
 - alcoholic dementia, 411
 - alcoholic myopathy, 412–13
 - alcoholic polyneuropathy, 413–14
 - alcohol withdrawal, 411
 - fetal alcohol syndrome, 414–15
 - Marchiafava–Bignami disease, 412
 - pharmacological aspects of, 410
- neuromuscular disease (NMD), 225*t*, 577
- neuromuscular junction (NMJ) disorders, 446
- neuromyelitis optica (NMO), 368
 - clinical and laboratory features of, 375
 - epidemiology and immunogenetics of, 377
 - pathology and pathogenesis of, 375–6
- neuronal ceroid lipofuscinoses (NCLs), 98, 600–601
- neuro-ophthalmology, 495
- neuro-otology
 - epidemiological features of, 485
 - international considerations in patients with, 485
- neuropathy, 577–8
 - immune-mediated, 425
 - from nutritional causes and alcoholism, 431
 - from vitamin B₁₂ deficiency, 430
- neuropathy, ataxia, retinitis pigmentosa (NARP), 622
- neuropsychic-Behçet's syndrome, 76
- neuro-retinitis, 498
- neurosarcoidosis. *See* Sarcoidosis
- neurosyphilis, 139, 266
 - clinical features, 266–8
 - investigations, 268
 - pathophysiology, 266
 - treatment
 - follow-up, 268
 - of HIV positive patient with, 268
- neurotoxic disorders
 - bacterial toxins, because of, 398
 - food poisoning, because of, 395
 - heavy metal intoxication
 - arsenic, 391
 - elemental mercury, 393
 - inorganic mercury salts, 393
 - lead, 391–2
 - manganese, 392–3
 - mercury, 393
 - organomercury compounds, 393–4
 - thallium, 394
 - household accident, because of, 397
 - industrial intoxication, because of
 - acrylamide, 395
 - carbon disulfide (CS₂), 395–6
 - n*-hexane, 396
 - toluene, 397
 - pesticides, because of, 394–5
 - plant toxins, 398
 - postnatal, 391
- niacin deficiency, chronic 404
- Nipah virus, 326–7
- nocturnal frontal lobe epilepsy (NFLE), 575
 - clinical features of, 575
 - differential diagnosis of, 575
 - evaluation of patients, 575–6
 - genetics, 575
 - treatment of, 576
- non-Hodgkin's lymphoma, 360
- non-invasive positive pressure ventilation (NIPPV), 202, 222
- non-necrotizing granulomas, 79
- non-steroidal anti-inflammatory drugs (NSAIDs), 125, 418
- normal-appearing white matter (NAWM), 367
- normal pressure hydrocephalus (NPH), 137, 157, 492
 - evaluation of a patient with, 138
 - management of, 137
- nuclear envelopathies, 452

- nucleoside reverse transcriptase inhibitors (NRTIs), 354
- nutritional optic neuropathy, 499–500
- nutrition, components of, 408
- obstructive hydrocephalus, 531
- obstructive sleep apnea (OSA), 557, 563
 - clinical features of, 564
 - epidemiological features of, 563
 - investigations, 564
 - pathophysiology, 563–4
 - treatment
 - continuous positive airway pressure (CPAP), 564–5
 - general, surgical success for, 565
 - oral appliances, 565
- occipital lobe epilepsy (OLE), 103
- occipital neuralgia, 677
- ocular disorders, 496
- oculopharyngeal muscular dystrophy (OPMD), 231, 451
 - clinical features of, 232
 - epidemiological features of, 231
 - history, 231
 - investigations, 232
 - pathophysiology, 231–2
 - treatment and management of, 232
- oligemia, 36
- oligoastrocytomas (OA), 514
- oligoclonal bands (OCB), 375
- oligodendroglial tumors, 514
- oligodendrogliomas (OD), low grade, 514
 - epidemiology and prognosis, 514
 - management of, 515–16
 - chemotherapy, 516
 - radiation therapy, 516
 - surgery, 515–16
 - pathology and molecular biology, 515
 - prognostic factors, 514–15
 - treatment, 515
- ophthalmoplegia, 621
- opioids, 667–8
- Oppenheim dystonia, 168–9
- Oppenheimer's dystonia, 481
- opportunistic infections (OIs)
 - diffuse complications for, 356–7
 - focal complications for, 357–9
- optic nerve atrophy, 621
- optic nerve sheath meningioma, 500
- optic neuritis, 379, 497
- Optic Neuritis Treatment Trial (ONTT), 497
- optic spinal MS (OSMS), 368
- oral contraceptive pill (OCP), 40
- organophosphates (OP) intoxication, 446
- Orientia tsutsugamushi*, 303
- osmotic demyelination syndrome (ODS)
 - clinical features of, 386–7
 - epidemiological features of, 386
 - pathophysiological features of, 386
 - treatment of, 387–8
- oxcarbazepine, 107, 110
- Paget's disease, 583
- pain disorders, 661
 - approach to patient with, 666
 - central pain, 665–6
 - classification of, 661
 - complex regional pain syndromes, 665
 - descending modulatory systems, 663
 - due to systemic disorders, 666
 - entrapment neuropathies, 665
 - goal of therapy, 666
 - opioids, 667–8
 - mechanism, diagnostic features, molecular target, and drugs, 667*t*
 - pain transmission and modulation, 661–3
 - visceral pain, 663–4
- Panayiotopoulos syndrome (PS), 99
 - features of, 100
 - interictal EEG, 100*f*
- pantothenate kinase gene (PANK2), 142
- pantothenic acid, 402
- paraneoplastic cerebellar degeneration (PCD), 551
- paraneoplastic cephalomyelitis (PEM), 551–2
- paraneoplastic neurologic disorders (PND), 550
 - diagnosis of, 550
 - treatment, 551
- paraneoplastic sensory neuronopathy (PSN), 552
- paraneoplastic syndromes, and antibody associations, 550*t*
- parasomnias, 578
- parietal lobe epilepsy (PLE), 103
- parkinsonism, 152
 - infectious and post-infectious, 158
 - linked to chromosome 17 (FTDP-17), 156–7
 - toxin-induced, 157–8
 - vascular, 157
- parkinsonism-dementia complex of Guam (PDC), 157
- Parkinson's disease (PD), 128, 392, 578. *See also* dementia
 - clinical features of, 128–9, 160
 - differential diagnosis, 129, 161
 - gene loci identified for, 160
 - management of advanced, 163–5
 - management of early, 161
 - pharmacotherapy for neuroprotection, 161–2
 - pharmacotherapy for symptom control, 162–3
 - neuropathology, 159
 - treatment, 129–30, 161
 - treatment strategies for tremors in, 151*t*
- paroxysmal dyskinesia, 660
- paroxysmal nocturnal dystonia (PND), 575. *See also* nocturnal frontal lobe epilepsy (NFLE)
- Parsonage–Turner syndrome, 432
- patent foramen ovale (PFO), 14
- pathological hypersomnias, 578
- Pearson syndrome (PS), 620
- pediatric epidural metastases, 548
- pediatric neurotransmitter disorders, 590
- pediatric parasomnias, 572
- Pelizaeus–Merzbacher disease, 606
- periodic leg movements (PLM), 567
- periodic limb movement disorder (PLMD), 567, 577
- periodic sharp-wave complexes (PSWC), 338
- peripheral nervous system (PNS), 351, 394
- peripheral neuropathies (PN), 363–4
- peroneal neuropathy, 437
- persistent foramen ovale (PFO), 34
- pesticides, 394–5
- phenylalanine hydroxylase, deficiency of. *See* phenylketonuria
- phenylketonuria, 612
 - clinical features, 613
 - epidemiology, 613
 - treatment, 613
- phenytoin, 107
- platelet-derived growth factor receptors (PDGFR), 530
- Podophyllotoxin (Bajiaolian), 399
- Podophyllum pelatum*, 399
- point mutations, in mtDNA, 621
- polio virus, 212
- poly(A) binding protein nuclear 1 (PABPN1) gene, 231
- polyangitis overlap syndrome, 55
- polyarteritis nodosa (PAN), 54, 429
- polychlorinated biphenyls (PCBs), 399
- polycythemia, 23
- polymerase chain reaction (PCR), 306, 312
- polymorphonuclear leucocytes, 305
- polymyalgia rheumatica (PMR), 45
- polymyositis (PM), 363
 - association conditions for, 469–70
 - clinical features of, 469
 - differential diagnosis of, 471
 - immunopathological features of, 471*f*
- polyneuropathy, 402–3
 - causes of, 416*t*
 - chronic inflammatory demyelinating. *See* chronic inflammatory demyelinating polyneuropathy
 - diagnostic considerations in patients with, 417*f*
- Pompe's disease, 606
- porphyrias, 640
 - clinical picture, 641–2
 - differential diagnosis, 643
 - geographic and epidemiological considerations, 640–641
 - neurological manifestations and, 642
 - pathogenesis of neurological dysfunction, 642
 - types of, 640
- porphyric attack. *See also* porphyrias
 - caused by antiepileptic medications, 642–3
- posterior reversible encephalopathy syndrome (PRES), 36, 37
- posterior subcapsular cataract (PSC), 499
- postgastroplasty polyneuropathy, 409
- post-malaria neurological syndromes (PMNS), 287
- postmedian sternotomy, 432
- post-traumatic dystonia, 659–60
- post-traumatic movement disorders (PMDs), 659
 - clinical features, 659–60
 - epidemiology, 659
 - Glasgow coma scale (GCS) of, 659
 - investigations, 659–60
 - management of, 659–60
 - pathophysiology, 659
- post-traumatic myelomalacic myelopathy (PPMM), 653
- post-traumatic tremor, 659–60
- post-viral cerebellitis
 - clinical features of, 329
 - epidemiological features of, 329
 - methods for investigating, 329–30
 - pathogenesis of, 329

- Pott's disease, 547
 praziquantal, 299
 precipitating hemorrhagic transformation, 35
 prednisolone, 47, 50, 81
 primary amoebic meningoencephalitis (PAM), 279
 primary angiitis of the central nervous system, 49
 primary carnitine deficiency (PCD), 632
 primary central nervous system lymphoma (CNSL), 535
 epidemiology, 535
 HIV / AIDS-related CNSL, 537
 investigations, 535–6
 prognosis and treatment, 536–7
 salvage therapy, 537
 treatment guidelines, 537–8
 treatment-related toxicity, 537
 primary central nervous system lymphoma (PCNSL)
 clinical features of, 360
 epidemiological features of, 360
 factors associated with increased survival in, 360f
 investigating procedures for, 360
 pathophysiological features of, 360
 treatment and management of, 360–61
 primary lateral sclerosis (PLS), 199, 203
 clinical features, 203–4
 epidemiology, 203
 investigations, 204
 pathophysiology, 203
 treatment and management of, 204
 primitive neuroectodermal tumors (PNET), 530
 prion diseases, 134
 causes of, 336
 clinical features of
 genetic TSEs, 337
 iatrogenic CJD (iCJD), 337
 kuru, 337
 sporadic CJD (sCJD), 337
 variant CJD (vCJD), 337–8
 epidemiological features of, 336–7
 methods for investigating
 brain biopsy, 339
 cerebrospinal fluid, 338
 electrophysiological studies, 338
 genetic analysis, 339
 neuroimaging, 338
 postmortem investigations, 339
 pathophysiological features of, 337
 preventive measures for, 339
 therapeutic approaches to, 339
 PRNP gene, 337
 procarbazine, 515
 progressive external ophthalmoplegia (PEO), 620
 progressive external ophthalmoplegia, chronic (CPEO), 451
 progressive multifocal leukoencephalopathy (PML), 139–40, 331, 333
 progressive muscular atrophy (PMA), 199
 progressive muscular dystrophies, 449
 progressive myoclonic epilepsy (PME), molecular genetics of, 96f
 progressive rubella panencephalitis, 331, 333
 progressive rubella panencephalitis, 332
 progressive supranuclear palsy (PSP), 152
 clinical features, 152–3
 epidemiology, 152
 investigations, 153
 management, 153
 neuropathology, 152
 NINDS–SPSP criteria for the diagnosis of, 153
 propionic and methylmalonic acidemia, 611
 epidemiology, 611
 pathophysiology and clinical features, 611–12
 treatment and management, 612
 proteinuria, 646
 prothrombotic disorders, 23–4, 33
 protozoans
 of neurologic importance, 278
 pathogenic for man, 278
 psychiatric disorders, 88. *See also* epilepsy
 psychiatric disturbance, 621
 psychogenic movement disorders (PMDs), 197
 clinical features, 197
 diagnosis, 197
 epidemiology, 197–8
 prognosis, 198
 treatment of, 198
 Puffer fish poisoning, 398
 pupillary abnormalities, clinical approach to, 503
 pure vascular and mixed dementia, 130–131
 Purkinje's cells, of cerebellar cortex, 412
 pyknolepsy, 95
 pyridoxine-dependent epilepsy (PDE), 593

 quinidine, 288

 rabies
 clinical features of, 321
 epidemiological features of, 320
 laboratory features of, 321
 pathogenesis of, 320
 pathological features of, 320–321
 treatment and management procedures for, 321
 radiation optic neuropathy (RON), 499
 Radiation Therapy Oncology Group (RTOG), 508
 rapid eye movement (REM), 573
 epidemiology and risk factors, 573
 rare stroke syndromes, 38
 recombinant tissue plasminogen activator (r-TPA), 10
 recurrent ependymoma, 523–4
 recurrent meningitis, 238
 recurrent viral meningitis, 310
 red blood cells (RBCs), 301, 401
 Refsum's disease, 423, 608
 relative afferent pupillary defect (RAPD), 495
 REM behavior disorder (RBD), 573
 clinical course, 574
 clinical features and differential diagnoses, 573–4
 epidemiology and risk factors, 573
 investigations, 574
 management, 574
 pathophysiology of, 573
 REM parasomnia, 578
 restless legs syndrome (RLS), 566, 577
 augmentation, dopaminergic therapy in, 568
 clinical features, 567
 diagnostic criteria of, 567f
 epidemiology, 566
 investigations, 567
 pathophysiology, 566
 pharmacological treatment and management of, 568

 reticuloendothelial system (RES), 308
 retinopathy, 621
 retroperitoneal hemorrhage, 435
 rhabdovirus. *See* rabies
 rheumatoid arthritis (RA), 67
 clinical features, 67–8
 management, 68
 neurological and psychiatric features associated with, 65–6
Rhipicephalus sanguineus, 303
Rickettsia conorii, 303
 Rickettsial disease, 293
 clinical features of, 304f, 305
 diagnosis of, 303
 epidemiological features of, 303, 304f
 geographic distribution of, 305f
 treatment of, 307
Rickettsia prowazekii, 303
Rickettsia typhi, 303
 rickettsioses
 categories of, 303
 spotted fever group
 Mediterranean spotted fever, 306
 Rocky Mountain spotted fever, 305–6
 typhus group
 epidemic typhus, 306
 murine typhus, 306
 scrub typhus, 306
 Rift Valley encephalitis, 327
 Riley–Day syndrome, 422
 Rocky Mountain spotted fever (RMSF), 305–6
 rolandic epilepsy (RE), 99
 rye-like symptoms, 633

 Sanfilippo's syndrome, 605
 Santavouri–Haltia disease, 600
 sarcoidosis, 79
 clinical features, 79–80
 epidemiology, 79
 investigations, 80
 pathophysiology, 79
 treatment and management of, 80–82
 scapular winging, atrophy, 221f
 scapuloperoneal muscular dystrophy, 225–6, 226f
 scapuloperoneal neuropathy, 226
 scapuloperoneal syndrome, 225
 clinical features, 225
 schistosoma, life cycle, 298f
Schistosoma mansoni, 547
 schistosomiasis, 297, 547
 sclerosing panencephalitis, subacute (SSPE), 331, 333
 SCN1A mutation, 101
 secondary hereditodegenerative dystonias, 170
 secretion of antidiuretic hormone (SIADH), 322
 seizures, 642
 selective serotonin reuptake inhibitors (SSRIs), 573
 sensory nerve action potentials (SNAPs), 426
 septic cavernous sinus thrombosis, 250
 bacteriology, 250
 laboratory findings, 250
 neuroimaging features, 250, 251f
 therapeutic protocol, 251
 septic cortical thrombophlebitis, 252
 septic CVT vs. aseptic CVT, 251

- septic lateral sinus thrombosis, 251
 common isolates, 251
 neuroimaging findings, 251
 symptoms in, 251
 treatment, 251
- septic superior sagittal sinus thrombosis, 251–2
 common symptoms, 252
 contrast enhanced CT scan, 252
 frequent isolates, 252
 treatment, 252
- serotonin, 134
- serotonin norepinephrine re-uptake inhibitors (SNRIs), 680
- serum creatine kinase (SCK), 217, 232
- severe myoclonic epilepsy in infancy (SMEI), 90
- sexual dysfunction, 372
- sialidoses, 98
- sickle cell anemia, 23
- sickle cell disease (SCD), 33
- single fiber electromyography (SFEMG), 439, 445
- sinus venous thrombosis (SVT), 33, 34
- Sjögren's syndrome (SS), 68, 429, 470
 management, 68
 neurological and psychiatric features associated with, 65–6f
- skeletal muscle disorders, 457
- sleep-disordered breathing (SDB), 577
- sleep disorders, 86
 international classification of, 559f
- sleep fragmentation, 558
- sleep timing and duration, regularity in, 569
- sly syndrome, 605
- small-cell lung carcinoma (SCLC), 442
- smoking, 9
- SOD1 protein, 200
- sphingomyelinases, 602
- spinal cord injury (SCI), 652
 epidemiology, 652
 investigations, 653
 pathophysiology and clinical features, 652–3
 treatment, 653
- spinal cord injury without radiographic abnormality (SCIWORA), 653
- spinal cord stroke, 42
 clinical features of, 42
 hemorrhage, 43
 ischemia and infarction, 42–3
 spinal vascular malformations, 43
- epidemiology, 42
 investigations, 43
 pathophysiology, 42
 treatment and management of, 44
- spinal muscular atrophy (SMA), 423
 classification of, 208f
 clinical features, 208
 epidemiology, 208
 investigations, 208–9
 non-proximal SMA, 210
 distal SMA, 210
 scapuloperoneal SMA, 210
 proximal SMA, 209
 SMA type I, 209
 SMA type II, 209
 SMA type III, 209–10
 SMA type IV, 210
 spinobulbar neuronopathy type Kennedy, 210
- spinal pain, 579
- spinal schistosomiasis, 297
 investigations, 298–9
 treatment, 299
- spinocerebellar ataxia (SCA) syndromes, 491
- spondyloarthropathies, 83.
See also ankylosing spondylitis (AS)
- sporadic inclusion body myositis (sIBM), 474
- Staphylococcus aureus*, 470
- starvation, 408
- steroid-responsive autoimmune encephalopathies, 142
- St Louis encephalitis
 clinical features of, 324
 epidemiological features of, 324
 investigation and management of, 325
 pathological features of, 324
- storage disorders, 600
- Strachan's syndrome, 408–9
- stroke, 267, 577
 antiphospholipid antibodies and, 24
 etiology, 1
 and migraine, 36
 mortality and incidence, 1
 periprocedural, post-operative and in-hospital, 37–8
 and substance abuse, 36
- stroke-like episodes, 620
- Sturge-Weber syndrome (SW), 484
- subacute sclerosing panencephalitis (SSPE), 331, 333
- subarachnoid hemorrhage
 clinical classification of, 30
 clinical features, 30
 conventional catheter angiography, 30–31
 epidemiology, 29
 pathophysiology, 29
 hydrocephalus, 30
 recurrence of, 30
 vasospasm, 30
 prognosis, 30
 risk factors, 30
 treatment and management of, 31
 vasospasm, 31
- subcortical ischemic vascular disease (SIVD), 131
- subdural empyema, 245
 clinical features, 245
 epidemiology/pathophysiology, 245
 investigations, 245–6
 laboratory studies, 246
 treatment and management of, 246–7
- substance abuse related stroke, 36
- succinic semialdehyde dehydrogenase, 592
- sudden unexpected death in epilepsy (SUDEP), 85–6. *See also* epilepsy
- suprachiasmatic nucleus (SCN), 569
- Susac's syndrome, 55, 56
- Swan-Ganz pulmonary artery catheter, 31
- Sydenham's chorea, 177
- symptomatic LRE, 102
- syphilis. *See* neurosyphilis
- syphilitic dementia, 139
- syringomyelia, 587
 clinical features, 587–8
 epidemiology, 587
 investigations, 588
- pathophysiology, 587
 treatment and management of, 588–9
- systemic autoimmune disorders, 142
- systemic inflammatory response syndrome (SIRS), 448
- systemic lupus erythematosus (SLE), 59, 63, 142, 177
 clinical features and investigations, 64, 67
 criteria for classification of, 64f
 epidemiology, 63
 management, 68
 neurological and psychiatric features associated with, 65–6
 pathophysiology of neurological features of, 63, 64
- systemic lupus erythematosus (SLE), 496
- systemic lymphoma, 361
- systemic sclerosis, 70
 central nervous system involvement, 71
 curative therapy for, 71
 epidemiology, 70
 initial symptoms of, 70
 investigations and diagnosis, 71
 neurological involvement with, 70
 pathological features of, 70
 peripheral neuropathy, 71
- tabes dorsalis, 267
- Takayasu's arteritis, 51, 55
 clinical manifestations, 51, 53
 epidemiology, 51
 etiology of, 51
 geographical variation of, 52f
 laboratory findings, 52
 pathology, 51
 treatment of, 52
- Tangier disease, 608
- tarsal tunnel syndrome, 437
- T cell antigen receptor (TCR), 470
- temporal-artery biopsy (TAB), 46
- temporal lobe epilepsy (TLE), 102–3
- tension-type headache (TTH), 671
- teprostilin, 62
- tetanus, 463f
- Tetrodotoxin, 398
- thiamine pyrophosphate (TPP), 401
- thiotepa, 544
- thoracic outlet syndrome, 434
- thromboangiitis obliterans (TAO), 61
 clinical features, 61
 etiology, 61
 management, 62
 pathology, 61
- thrombotic thrombocytopenic purpura (TTP), 24
- thyroid-associated orbitopathy (TAO), 498
- tiagabine, 110
- tibial nerve entrapment, 437
- tick-borne encephalitis
 clinical features of, 324
 epidemiological features of, 323
 laboratory features of, 324
 management and treatment for, 324
 pathogenesis and pathological features of, 323
- tick-transmitted diseases, 303

- tics, 184
 classification, 184
 secondary causes of, 185
- tinnitus, common presentations of, 494
- tissue plasminogen activator (tPA), 35
- topectomy/cortectomy, 114
- topiramate, 110
- TOR1A* gene, 168
- Tourette syndrome (TS), 184
 diagnostic evaluation, 185
 etiology of, 184–5
 prognosis, 185–6
 treatment, 185
- toxic and metabolic disorders, 138
- Toxoplasma gondii*, 282, 350, 357
- toxoplasmosis, 282
 clinical features, 283
 epidemiology, 282
 investigations, 283
 pathophysiology, 282–3
 sulfadiazine and pyrimethamine,
 for treatment, 284
- transcranial color-coded duplex sonography
 (TCCS), 34
- transcutaneous electrical nerve stimulation
 (TENS), 680
- transient cerebral arteriopathy, 34
- transient global amnesia (TGA), 120
- transient ischemic attacks (TIAs), 2, 10
 clinical features, 3–4
 epidemiology
 ABCD score, 3
 risk factors for, 2
 management for patient
 brain imaging with computed
 tomography (CT), 4
 initial evaluation, 4
 pathophysiology
 categories of TIA etiology, 3
 differential diagnosis, 3
 treatment and management of, 4–5
- transient monocular visual loss (TMVL), 46
- transmissible spongiform encephalopathies (TSE).
See prion diseases
- transporter defects, 635–7
- traumatic amnesia, 121
- traumatic brain injury (TBI), 648
 clinical features, 649
 mild TBI/concussion, 649
 moderate-severe TBI, 649–50
 epidemiology, 648–9
 Glasgow coma scale, 648*t*
 investigations, 650
 pathophysiology, 649
 radiographic appearances of, 650*f*
 treatment and management of, 650–51
- traumatic nerve root avulsion, 432
- traumatic optic neuropathy (TON), 504
- trematodes. *See* schistosomiasis
- tremor, 146
 clinical approach to patients, 146
 clinical features, 146
 clinical presentation of, 146–9
 drugs and dosages for, 150*t*
 epidemiology of, 149
 investigations in, 149
 pathophysiology of, 149
 treatment of, 150–51
- Trichinella spiralis*, 300
- Trichinosis
 causes of, 300
 clinical features of, 300
 differential diagnosis of, 300
 epidemiology of, 300
 treatment of, 300
- trigeminal neuralgia
 clinical features, 675–6
 epidemiology, 675
 investigation, 676
 pathophysiology, 675
 treatment and management of, 676
- triorthocresyl phosphate (TOCP), 394
- true neurogenic thoracic outlet syndrome, 434
- Trypanosoma cruzi*, 290
- trypanosome, 290
- trypanosomiasis, 290
 chronic chagasic cardiomyopathy, 290
 clinical features of, 290
 epidemiology, 290
 investigations, 291
 treatment and management of, 291
- tuberculoid (TT), 263
- tuberculomas, 259
 investigations and diagnosis, 259
- tuberculosis (TB), 258
 clinical features of, 358
 epidemiology, 258
 investigating procedures for, 358
 medication, 260
 neurosurgical treatment, 260
 pathophysiology, 258
- tuberculous meningitis (TBM), 258–60, 356–7
 investigations and diagnosis, 259
- tuberous sclerosis (TS), symptoms of, 483
- ulnar neuropathy, 437
- Unverricht–Lundborg disease (ULD), 97
- upper motor neuron (UMN) disorder, 203
- urea cycle disorders, 610
 clinical presentation, 611
 epidemiology, 610–611
 neurological manifestations of, 611*t*
 pathophysiology and treatment, 611
- U1 ribonucleoprotein (U1-RNP), 73
- vagal nerve stimulation (VNS), 114–15
- valproate, 110
- varicella zoster (VZV), 330, 345
- vascular adhesion molecule (VCAM), 373
- vascular chorea, 177
- vascular dementia (VaD), 130
 denetic disorders, 131
 diagnosis of, 131
 diagnostic criteria for, 130*t*
 symptomatic treatment of, 132
 treatment, 131–2
- vascular endothelial growth factor
 (VEGF), 530
- vasculitic neuropathies, 429
- vasculitis, 54
 with oral contraceptive use, 55
 secondary to infection, 55
- Veneral Disease Laboratory Research (VDLR)
 test, 34
- Venezuelan equine virus, 325–6
- vestibular ocular reflex (VOR), 488
- video-EEG (v-EEG), 104
- vincristine, 515, 530
- viral encephalitides, 140
- viral encephalitis
 clinical and laboratory features of, 314–15
 differential diagnoses of, 315, 316*t*, 318
 distribution of viruses causing, 317*f*
 epidemiological and etiological features of, 314
 geographical location of, 315
 history of exposure of, 315–18
 laboratory investigations of, 316*t*
 management and prognosis of, 318–19
 pathological features of, 314
 specific clinical features of viruses causing, 318*t*
 symptoms of, 314
- viral meningitis
 acute
 clinical features of, 308–9
 signs and symptoms of, 309*t*
 bacterial meningitis, distinguishing features
 with, 311*t*
 causes of, 309*t*
 chronic, 310
 clinical features of
 acute viral meningitis, 309–10
 chronic viral meningitis, 310
 recurrent viral meningitis, 310
 differential diagnosis of, 310–311
 epidemiological functions of, 308
 etiology of, 312
 investigating procedures for, 311–12
 pathophysiology of, 308–9
 recovery and prognosis of patients from, 313
 treatment and management of, 312–13
- visual evoked potential (VEP), 497
- visual evoked responses, 370
- visual loss
 acute to subacute, 497
 clinical approach to, 495
 clinical aspects of transient, 496*f*
 monocular sudden, 496–7
 pattern of, 495–6
- vitamin deficiency
 effects of, 401
 nicotinic acid, of, 403–4
 vitamin A, of, 406
 of vitamin B₁
 central pontine myelinolysis, 403
 cerebellar degeneration, 403
 Gayet–Wernicke encephalopathy, 402
 Korsakoff’s syndrome, 402
 polyneuropathy (neuropathic beri-beri),
 402–3
 of vitamin B₅, 405
 of vitamin B₆, 405
 of vitamin B₁₂, 404–5
 of vitamin C, 406
 of vitamin D, 406
 of vitamin E, 406
- voltage-gated calcium channels (VGCC), 442
- von Gierke’s disease, 605–6
- von Hippel–Lindau disease (VHL), 483

- Waldenström's macroglobulinemia, 428
- Wegener's granulomatosis (WG), 57, 429
- Wernicke–Korsakoff's disease, 431
- Wernicke–Korsakoff syndrome (WKS), 121, 138
- Wernicke's encephalopathy, 409, 412
- Western equine virus, 325
- West Nile encephalitis
 - clinical features of, 323
 - epidemiological features of, 322
 - laboratory features of, 323
 - pathological features of, 322–3
 - treatment and management of, 323
- West syndrome (WS), 92–3
- whiplash associated disorders (WAD), 655
 - clinical features, 655–6
 - epidemiology, 655
 - management, 656
- Whipple's disease, 140, 254–6
- white blood cell (WBC), 301, 305
- white cell count (WCC), 356
- Wilson's disease (WD), 141, 392, 635–6, 644
 - Kayser–Fleischer ring in, 645*f*
 - diagnostics, 645
 - genetics, 645
 - magnetic resonance images in, 646*f*
 - motor impairment in, 644
 - neurological presentations, 644
 - ophthalmic involvement in, 644
 - pathophysiology of, 644
 - treatment, 645–6
- Wolff–Parkinson–White (WPW) syndrome, 621
- xanthine oxidase inhibitor, 639
- xeroderma pigmentosum (XP), 484
- x-linked Emery–Dreifuss muscular dystrophy, 233
- x-linked muscular dystrophy, 233
- zonisamide, 110–11
- zoonotic viruses, 315
- zygomycosis, 276

